The latest price target for Pediatrix Medical Group (NYSE:MD) was reported by UBS on February 21, 2025. The analyst firm set a price target for $18.50 expecting MD to rise to within 12 months (a possible 27.15% upside). 18 analyst firms have reported ratings in the last year.

The latest analyst rating for Pediatrix Medical Group (NYSE:MD) was provided by UBS, and Pediatrix Medical Group maintained their neutral rating.

The last upgrade for Pediatrix Medical Group Inc happened on September 26, 2024 when Jefferies raised their price target to $14. Jefferies previously had a hold for Pediatrix Medical Group Inc.

There is no last downgrade for Pediatrix Medical Group.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pediatrix Medical Group, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pediatrix Medical Group was filed on February 21, 2025 so you should expect the next rating to be made available sometime around February 21, 2026.

While ratings are subjective and will change, the latest Pediatrix Medical Group (MD) rating was a maintained with a price target of $16.50 to $18.50. The current price Pediatrix Medical Group (MD) is trading at is $14.55, which is out of the analyst’s predicted range.